Glaukos/$GKOS
1D1W1MYTD1Y5YMAX
Capital at risk
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
- Ticker
- $GKOS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,094
- Headquarters
- Aliso Viejo, United States
- Website
- www.glaukos.com
Glaukos Metrics
BasicAdvanced
$10B
-
-$3.25
0.76
-
Price and volume
Market cap
$10B
Beta
0.76
52-week high
$191.62
52-week low
$73.16
Average daily volume
670K
Financial strength
Current ratio
5.04
Quick ratio
4.155
Long term debt to equity
0.151
Total debt to equity
0.151
Interest coverage (TTM)
-16.10%
Profitability
EBITDA (TTM)
-37.025
Gross margin (TTM)
79.12%
Net profit margin (TTM)
-30.68%
Operating margin (TTM)
-12.89%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-5.20%
Return on equity (TTM)
-25.98%
Valuation
Price to revenue (TTM)
16.231
Price to book
14.81
Price to tangible book (TTM)
20.68
Price to free cash flow (TTM)
-815.586
Free cash flow yield (TTM)
-0.12%
Free cash flow per share (TTM)
-0.21
Growth
Revenue change (TTM)
41.55%
Earnings per share change (TTM)
96.33%
3-year revenue growth (CAGR)
27.34%
10-year revenue growth (CAGR)
21.02%
3-year earnings per share growth (CAGR)
7.11%
10-year earnings per share growth (CAGR)
57.51%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Analyst projections of the future price of Glaukos stock.
Bulls say / Bears say
Record Q2 net sales of $185.6 million, up 50% year-over-year, prompted Glaukos to raise its full-year 2026 net sales guidance to $680–$700 million. (Reuters)
CMS assigned a product-specific J-code (J2789) for Epioxa, effective July 1, 2026, streamlining reporting and reimbursement processes to support broader market access. (SEC.gov)
Within its U.S. glaucoma franchise, Q2 net sales grew 64% year-over-year to $118.5 million, driven by approximately $74 million in iDose TR sales, underscoring rapid physician adoption and market penetration. (EarningsCalls.dev)
Despite revenue growth, Glaukos reported a GAAP net loss of $18.4 million in Q2 2026, highlighting ongoing unprofitability. (SEC.gov)
Selling, general and administrative expenses rose 39% to $116.1 million in Q2 2026 (from $83.4 million), reflecting significant cost pressure as the company scales operations. (SEC.gov)
International revenue growth was partially offset by reimbursement challenges in Germany, posing a headwind to overseas expansion. (SECInfo.com)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Upcoming events
No upcoming events
Glaukos News
AllArticlesVideos
Funds containing Glaukos
AllEURUSDGBP
Fund name | Fund size | $GKOS weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.64% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.58% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.58% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.32% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.